Dr Rajani Katta joins Ethics Talk to discuss her article, coauthored with Dina H. Zamil, Emily K. Burns, and Dr Ariadna Perez-Sanchez: “Do You Know How to Assess Risks Posed by Over-the-Counter Vitamin A Supplements?”
Jesse Feierabend-Peters, MD, PhD and Hugh Silk, MD, MPH
Despite availability of good national oral health curricula for medical trainees, most physicians are ill-equipped to identify oral cancers or avoid unnecessary referrals.
AMA J Ethics. 2022;24(1):E19-26. doi:
10.1001/amajethics.2022.19.
This narrative illuminates need for students and clinicians to be well prepared to face ethically and structurally complex realities of identifying and responding to children.
AMA J Ethics. 2023;25(2):E159-165. doi:
10.1001/amajethics.2023.159.
Annika Brakebill, A. Mark Fendrick, MD, and Jeffrey T. Kullgren, MD, MS, MPH
These key steps are ones health sector stakeholders should take to help patients and clinicians use pricing information to inform health decision making.
AMA J Ethics. 2022;24(11):E1034-1039. doi:
10.1001/amajethics.2022.1034.
Jing Li, PhD, Robert Tyler Braun, PhD, Sophia Kakarala, and Holly G. Prigerson, PhD
For dying patients and their loved ones to make informed decisions, physicians must share adequate information about prognoses, prospective benefits and harms of specific interventions, and costs.
AMA J Ethics. 2022;24(11):E1040-1048. doi:
10.1001/amajethics.2022.1040.
Fragmentation in US health care delivery streams and shortcomings in formal quality measures mean that transparency could be more useful to policymakers and regulators than patients.
AMA J Ethics. 2022;24(11):E1075-1082. doi:
10.1001/amajethics.2022.1075.
Sarosh Nagar, Leah Z. Rand, PhD, and Aaron S. Kesselheim, MD, JD, MPH
This article analyzes differences in prescription drug pricing transparency practices among 3 Organisation of Economic Co-operation and Development member nations.
AMA J Ethics. 2022;24(11):E1083-1090. doi:
10.1001/amajethics.2022.1083.